HUP0203084A2 - Use of baff receptor (bcma) as an immunoregulatory agent - Google Patents

Use of baff receptor (bcma) as an immunoregulatory agent

Info

Publication number
HUP0203084A2
HUP0203084A2 HU0203084A HUP0203084A HUP0203084A2 HU P0203084 A2 HUP0203084 A2 HU P0203084A2 HU 0203084 A HU0203084 A HU 0203084A HU P0203084 A HUP0203084 A HU P0203084A HU P0203084 A2 HUP0203084 A2 HU P0203084A2
Authority
HU
Hungary
Prior art keywords
baff
production
cell
subject
inhibiting
Prior art date
Application number
HU0203084A
Other languages
English (en)
Inventor
Ambrose
Browning
Mackay
Schneider
Thompson
Tschopp
Original Assignee
Apotech R & D Sa
Biogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27386828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0203084(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Apotech R & D Sa, Biogen filed Critical Apotech R & D Sa
Publication of HUP0203084A2 publication Critical patent/HUP0203084A2/hu
Publication of HU227008B1 publication Critical patent/HU227008B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

(57) A találmány tárgyát a BAFF-receptor (BAFF-R) és a receptort gátlómolekulák alkalmazása képezi B-sejtek és immunglobulinokexpressziójának stimulálására vagy gátlására.A találmány tárgyátközelebbről a BAFF-R-polipeptid, BAFF-R-polipeptidet tartalmazó kiméramolekulák és antiBAFF-R ellenanyag homológok és azok fragmentumainakalkalmazása képezi B-sejtproliferáció, immunglobulin-termelés,dendritikus sejt által közvetített B-sejtproliferáció és/vagy B-sejtérés gátlására alkalmas gyógyászati készítmények előállítására. Atalálmány tárgyát képezi továbbá B-sejtproliferációt gátló szeralkalmazása magas vérnyomás, vese-rendellenességek, és/vagy B-sejteslimfoproliferatív betegségek ketelésére alkalmas gyógyászatikészítmény előállítására, valamint a BAFF-R és BAFF közti kölcsönhatásgátlására alkalmas hatóanyagok alkalmazása BAFF-R BAFF közti jelátadásrészvételével zajló immunválasz kezelésére, szupresszálására vagymódosítására alkalmas gyógyászati készítmény előállítására; BAFF-R-polipeptidre specifikus ellenanyag alkalmazása gyulladás gátlására. Atalálmány tárgyát képezik a fentieket tartalmazó gyógyászatikészítmények is. Ó
HU0203084A 1999-08-17 2000-08-16 Use of baff receptor (bcma) as an immunoregulatory agent HU227008B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14937899P 1999-08-17 1999-08-17
US18168400P 2000-02-11 2000-02-11
US18353600P 2000-02-18 2000-02-18
PCT/US2000/022507 WO2001012812A2 (en) 1999-08-17 2000-08-16 Baff receptor (bcma), an immunoregulatory agent

Publications (2)

Publication Number Publication Date
HUP0203084A2 true HUP0203084A2 (en) 2002-12-28
HU227008B1 HU227008B1 (en) 2010-04-28

Family

ID=27386828

Family Applications (3)

Application Number Title Priority Date Filing Date
HU1000128A HU227947B1 (en) 1999-08-17 2000-08-16 Use of baff receptor (bcma) as an immunoregulatory agent
HU1100145A HU230583B1 (hu) 1999-08-17 2000-08-16 BAFF-receptor (BCMA) alkalmazásai immunszabályozó szerként
HU0203084A HU227008B1 (en) 1999-08-17 2000-08-16 Use of baff receptor (bcma) as an immunoregulatory agent

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HU1000128A HU227947B1 (en) 1999-08-17 2000-08-16 Use of baff receptor (bcma) as an immunoregulatory agent
HU1100145A HU230583B1 (hu) 1999-08-17 2000-08-16 BAFF-receptor (BCMA) alkalmazásai immunszabályozó szerként

Country Status (29)

Country Link
US (7) US7083785B2 (hu)
EP (3) EP2314694A3 (hu)
JP (4) JP4787439B2 (hu)
KR (2) KR100897082B1 (hu)
CN (1) CN100447244C (hu)
AT (1) ATE360693T1 (hu)
AU (1) AU780240B2 (hu)
BG (1) BG106519A (hu)
BR (2) BR0013391A (hu)
CA (1) CA2383154C (hu)
CZ (1) CZ300364B6 (hu)
DE (1) DE60034579T3 (hu)
DK (1) DK1210425T4 (hu)
EA (1) EA004635B1 (hu)
EE (1) EE05673B1 (hu)
GE (1) GEP20053685B (hu)
HK (1) HK1043608B (hu)
HU (3) HU227947B1 (hu)
IL (3) IL148089A0 (hu)
IS (1) IS2955B (hu)
MX (1) MXPA02001665A (hu)
NO (2) NO331410B1 (hu)
NZ (1) NZ517782A (hu)
PL (2) PL207501B1 (hu)
RS (1) RS51157B (hu)
SK (2) SK288603B6 (hu)
TR (1) TR200201063T2 (hu)
UA (1) UA75049C2 (hu)
WO (1) WO2001012812A2 (hu)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8212004B2 (en) * 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6812327B1 (en) * 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US20030095967A1 (en) * 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US20050100548A1 (en) * 2001-07-24 2005-05-12 Biogen Idec Ma Inc. BAFF, inhibitors thereof and their use in the modulation of B-cell response
US6475987B1 (en) 1999-05-06 2002-11-05 National Jewish Medical And Research Center Tall-1 receptor homologues
DK1210425T4 (en) 1999-08-17 2015-08-10 Apotech R & D Sa BAFF receptor (BCMA), an immunoregulatory agent
UA74798C2 (uk) * 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
DK1255558T3 (da) * 2000-02-16 2006-10-23 Genentech Inc Anti-april antistoffer og hybridomaceller
US20040002068A1 (en) * 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US7371388B1 (en) * 2000-05-04 2008-05-13 Human Genome Sciences, Inc. Treatment of Sjogren's syndrome by administration of TR18 polypeptides
US20020086018A1 (en) * 2000-05-12 2002-07-04 Theill Lars Eyde Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3, and TACI
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
PT2275449T (pt) 2000-06-16 2016-12-27 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
US20030091565A1 (en) 2000-08-18 2003-05-15 Beltzer James P. Binding polypeptides and methods based thereon
UA83458C2 (uk) * 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
DE10049010A1 (de) * 2000-10-04 2002-04-18 Boehringer Ingelheim Int Transferrin-Polykation/DNS-Komplexe für die systemische Therapie von Tumorerkrankungen mit zytotoxischen Proteinen
SI1436003T1 (sl) 2001-05-24 2010-02-26 Zymogenetics Inc TACI-imunoglobulinski fuzijski proteini
WO2003014294A2 (en) * 2001-08-03 2003-02-20 Genentech, Inc. Tacis and br3 polypeptides and uses thereof
AU2003221256A1 (en) * 2002-02-21 2003-09-09 Biogen Idec Ma Inc. Use of bcma as an immunoregulatory agent
CA2492447A1 (en) * 2002-07-25 2004-02-05 Genentech, Inc. Taci antibodies and uses thereof
US7700317B2 (en) * 2003-03-28 2010-04-20 Biogen Idec Ma Inc. Truncated baff receptors
KR20060027801A (ko) * 2003-06-05 2006-03-28 제넨테크, 인크. Ｂ 세포 장애에 대한 조합 요법
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
MXPA06004301A (es) 2003-10-20 2006-06-05 Biogen Idec Inc Regimenes terapeuticos para antagonistas del factor de activacion de celulas b.
EP1709072A1 (en) * 2004-01-29 2006-10-11 Genentech, Inc. Variants of the extracellular domain of bcma and uses thereof
CA2585927A1 (en) * 2004-11-04 2006-05-18 Genentech, Inc. Polypeptides that bind baff and/or april
CA2590461A1 (en) 2004-12-23 2006-06-29 Laboratoires Serono S.A. Bcma polypeptides and uses thereof
AU2006209237B2 (en) * 2005-01-28 2010-06-24 Biogen Ma Inc. Use of BAFF to treat Th2-mediated conditions
EP1922080A2 (en) 2005-08-09 2008-05-21 ZymoGenetics, Inc. Methods for treating b-cell malignancies using taci-ig fusion molecule
CA2618763A1 (en) 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
KR20140077946A (ko) * 2005-10-13 2014-06-24 휴먼 게놈 사이언시즈, 인코포레이티드 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
CA2629306A1 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
CN101489573B (zh) 2006-05-15 2013-05-22 阿雷斯贸易股份有限公司 用TACI-Ig融合分子治疗自身免疫疾病的方法
AR072749A1 (es) 2008-07-17 2010-09-15 Novartis Ag Anticuerpos contra receptor del factor de la necrosis tumoral (baffr) y composiciones farmaceuticas
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
EP2396035A4 (en) * 2009-02-12 2012-09-12 Human Genome Sciences Inc USE OF ANTAGONISTS OF PROTEIN STIMULATING LYMPHOCYTES B TO PROMOTE GRAFT TOLERANCE
CN104877026B (zh) 2009-03-10 2019-10-25 比奥根Ma公司 抗-bcma抗体
EP3211094A3 (en) 2009-09-03 2017-11-01 F. Hoffmann-La Roche AG Methods for treating, diagnosing, and monitoring rheumatoid arthritis
CN101781680B (zh) * 2009-10-19 2012-05-09 南通大学附属医院 测定对人baff-r基因启动子活性影响因素的方法
CN101781679B (zh) * 2009-10-19 2012-05-23 南通大学附属医院 人baff-r基因启动子活性的测定方法
WO2011108008A2 (en) * 2010-03-04 2011-09-09 Transgene Biotek Ltd. Antibody for targeted induction of apoptosis, cdc and adcc mediated killing of cancer cells, tbl-cln1
KR20140022815A (ko) 2011-02-28 2014-02-25 제넨테크, 인크. B-세포 길항제에 대한 반응을 예측하기 위한 생물학적 마커 및 방법
PT3415531T (pt) * 2011-05-27 2023-09-12 Glaxo Group Ltd Proteínas de ligação a bcma (cd269/tnfrsf17
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
WO2013116287A1 (en) 2012-01-31 2013-08-08 Genentech, Inc. Anti-ig-e m1' antibodies and methods using same
US10435474B2 (en) 2013-12-24 2019-10-08 Ossianix, Inc. Baff selective binding compounds and related methods
MX2016010128A (es) 2014-02-07 2017-02-02 Univ Mcmaster Acoplador trifuncional de antigeno de celulas t y metodos y usos del mismo.
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
CN106687483B (zh) 2014-07-21 2020-12-04 诺华股份有限公司 使用人源化抗-bcma嵌合抗原受体治疗癌症
DK3194443T3 (da) 2014-09-17 2021-09-27 Novartis Ag Målretning af cytotoksiske celler med kimære receptorer i forbindelse med adoptiv immunterapi
SI3226897T1 (sl) 2014-12-05 2021-08-31 Memorial Sloan Kettering Cancer Center Protitelesa, ki ciljajo na B-celični maturacijski antigen, in postopki uporabe
EP4310097A3 (en) 2014-12-05 2024-04-03 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
CN114773476A (zh) 2015-04-13 2022-07-22 辉瑞公司 治疗性抗体和它们的用途
PE20171653A1 (es) 2015-04-13 2017-11-13 Pfizer Receptores del antigeno quimerico dirigidos al antigeno de maduracion de celulas b
US20180298068A1 (en) 2015-04-23 2018-10-18 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
EP3331913A1 (en) 2015-08-07 2018-06-13 Novartis AG Treatment of cancer using chimeric cd3 receptor proteins
JP7118887B2 (ja) 2015-11-23 2022-08-16 ノバルティス アーゲー 最適化されたレンチウイルス移入ベクターおよびその使用
WO2017114497A1 (en) 2015-12-30 2017-07-06 Novartis Ag Immune effector cell therapies with enhanced efficacy
CN108778329B (zh) 2016-02-17 2022-09-16 西雅图基因公司 Bcma抗体和其用以治疗癌症和免疫病症的用途
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
JP7275446B2 (ja) * 2016-06-06 2023-05-18 シティ・オブ・ホープ Ｂａｆｆ－ｒ抗体及びその使用
AU2017281034B2 (en) 2016-06-21 2024-03-14 Teneobio, Inc. CD3 binding antibodies
WO2018052503A1 (en) 2016-09-14 2018-03-22 Teneobio, Inc. Cd3 binding antibodies
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
EP4215548A1 (en) 2016-12-21 2023-07-26 Teneobio, Inc. Anti-bcma heavy chain-only antibodies
WO2018140725A1 (en) 2017-01-26 2018-08-02 Novartis Ag Cd28 compositions and methods for chimeric antigen receptor therapy
EP3577134A1 (en) 2017-01-31 2019-12-11 Novartis AG Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
EP3589647A1 (en) 2017-02-28 2020-01-08 Novartis AG Shp inhibitor compositions and uses for chimeric antigen receptor therapy
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
JP7356354B2 (ja) 2017-05-12 2023-10-04 クリスパー セラピューティクス アクチェンゲゼルシャフト 細胞の操作のための材料及び方法並びに免疫腫瘍学におけるその使用
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
MX2020000342A (es) 2017-07-11 2020-08-17 Compass Therapeutics Llc Anticuerpos agonistas que se unen a cd137 humano y sus usos.
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
JP7227630B2 (ja) 2017-10-12 2023-02-22 マックマスター ユニバーシティー Ｙ１８２ｔ突然変異を有するｔ細胞－抗原カプラおよびその方法ならびに使用
TWI829655B (zh) 2017-10-18 2024-01-21 瑞士商諾華公司 用於選擇性蛋白質降解的組合物及方法
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
WO2019089798A1 (en) 2017-10-31 2019-05-09 Novartis Ag Anti-car compositions and methods
KR20200116077A (ko) 2017-11-01 2020-10-08 주노 쎄러퓨티크스 인코퍼레이티드 B 세포 성숙 항원에 특이적인 키메라 항원 수용체 및 암호화 폴리뉴클레오타이드
CA3080904A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
JP2021502979A (ja) 2017-11-15 2021-02-04 ノバルティス アーゲー Ｂｃｍａターゲティングキメラ抗原受容体、ｃｄ１９ターゲティングキメラ抗原受容体及び併用療法
WO2019100052A2 (en) 2017-11-20 2019-05-23 Compass Therapeutics Llc Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
KR20200096253A (ko) 2017-11-30 2020-08-11 노파르티스 아게 Bcma-표적화 키메라 항원 수용체, 및 이의 용도
CN112218651A (zh) 2018-01-08 2021-01-12 诺华公司 用于与嵌合抗原受体疗法组合的免疫增强rna
US20210038659A1 (en) 2018-01-31 2021-02-11 Novartis Ag Combination therapy using a chimeric antigen receptor
WO2019160956A1 (en) 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
US20210047405A1 (en) 2018-04-27 2021-02-18 Novartis Ag Car t cell therapies with enhanced efficacy
WO2019213282A1 (en) 2018-05-01 2019-11-07 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
EP3790629A1 (en) 2018-05-11 2021-03-17 CRISPR Therapeutics AG Methods and compositions for treating cancer
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
AU2019277029C1 (en) 2018-06-01 2024-01-04 Novartis Ag Binding molecules against BCMA and uses thereof
EP3802825A1 (en) 2018-06-08 2021-04-14 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
WO2019241426A1 (en) 2018-06-13 2019-12-19 Novartis Ag Bcma chimeric antigen receptors and uses thereof
AU2019297451A1 (en) 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
US11110123B2 (en) 2018-07-17 2021-09-07 Triumvira Immunologics Usa, Inc. T cell-antigen coupler with various construct optimizations
MX2021000488A (es) 2018-07-19 2021-04-12 Regeneron Pharma Anticuerpos anti-bcma x anti-cd3 biespecificos y usos de estos.
WO2020047449A2 (en) 2018-08-31 2020-03-05 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
EP3844267A2 (en) 2018-08-31 2021-07-07 Novartis AG Methods of making chimeric antigen receptor-expressing cells
AU2019402189B2 (en) 2018-12-20 2023-04-13 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
AU2020222346B2 (en) 2019-02-15 2021-12-09 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EA202192019A1 (ru) 2019-02-15 2021-11-02 Новартис Аг Производные 3-(1-оксо-5-(пиперидин-4-ил)изоиндолин-2-ил)пиперидин-2,6-диона и пути их применения
EP3930763A1 (en) 2019-02-25 2022-01-05 Novartis AG Mesoporous silica particles compositions for viral delivery
WO2020191316A1 (en) 2019-03-21 2020-09-24 Novartis Ag Car-t cell therapies with enhanced efficacy
EP3953455A1 (en) 2019-04-12 2022-02-16 Novartis AG Methods of making chimeric antigen receptor-expressing cells
WO2020219742A1 (en) 2019-04-24 2020-10-29 Novartis Ag Compositions and methods for selective protein degradation
US20220249558A1 (en) 2019-04-30 2022-08-11 Crispr Therapeutics Ag Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
JP2022537931A (ja) 2019-06-14 2022-08-31 テネオバイオ， インコーポレイテッド Ｃｄ２２及びｃｄ３に結合する多重特異性重鎖抗体
SG11202111943UA (en) 2019-07-02 2021-11-29 Hutchinson Fred Cancer Res Recombinant ad35 vectors and related gene therapy improvements
EP4065158A2 (en) 2019-11-26 2022-10-05 Novartis AG Chimeric antigen receptors binding bcma and cd19 and uses thereof
WO2021123996A1 (en) 2019-12-20 2021-06-24 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
EP4110377A2 (en) 2020-02-27 2023-01-04 Novartis AG Methods of making chimeric antigen receptor-expressing cells
CA3173394A1 (en) 2020-02-27 2021-09-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
BR112022021690A2 (pt) 2020-04-29 2022-12-20 Teneobio Inc Anticorpos de cadeia pesada multispecíficos com regiões constantes de cadeia pesada modificadas
EP4165169A1 (en) 2020-06-11 2023-04-19 Novartis AG Zbtb32 inhibitors and uses thereof
WO2021260528A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
CN116134027A (zh) 2020-08-03 2023-05-16 诺华股份有限公司 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
WO2022040586A2 (en) 2020-08-21 2022-02-24 Novartis Ag Compositions and methods for in vivo generation of car expressing cells
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
BR112023020832A2 (pt) 2021-04-08 2023-12-19 Marengo Therapeutics Inc Moléculas multifuncionais ligadas a tcr e seus usos
TW202309294A (zh) 2021-04-27 2023-03-01 瑞士商諾華公司 病毒載體生產系統
US11453723B1 (en) 2021-06-25 2022-09-27 Mcmaster University BCMA T cell-antigen couplers and uses thereof
CA3229746A1 (en) 2021-08-20 2023-02-23 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
DK0897390T3 (da) 1996-03-14 2004-03-08 Human Genome Sciences Inc Human tumornekrosefaktor-delta og -epsilon
EP2230307A1 (en) 1996-10-25 2010-09-22 Human Genome Sciences, Inc. Neutrokine alpha
AU5705898A (en) 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents
US5969102A (en) * 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
CA2232743A1 (en) 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5
WO1998046751A1 (en) 1997-04-16 1998-10-22 Amgen Inc. Osteoprotegerin binding proteins and receptors
WO1998055621A1 (en) 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
JP2002504818A (ja) 1997-06-06 2002-02-12 リジェネロン ファーマシューティカルズ，インコーポレイテッド リガンドファミリーのｎｔｎ−２メンバー
WO1999011791A2 (en) 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
WO1999012964A2 (en) * 1997-09-12 1999-03-18 Biogen, Inc. Kay - a novel immune system protein
ATE360032T1 (de) 1997-09-12 2007-05-15 Biogen Idec Inc Cystein-reiche rezeptoren-train
EA005411B1 (ru) * 1997-09-12 2005-02-24 Апотек Р Энд Д Са Применение антитела против полипептида april для получения лекарственного препарата для лечения опухолей
US6297367B1 (en) * 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
WO1999033980A2 (en) 1997-12-30 1999-07-08 Chiron Corporation Members of tnf and tnfr families
EP0947556B1 (en) * 1998-04-01 2004-11-10 Solvay Solexis, Inc. Compatible blends of polyvinylidene fluoride and aromatic polyimide
WO2000026244A2 (en) 1998-11-04 2000-05-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A novel tumor necrosis factor family member, drl, and related compositions and methods
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US7833529B1 (en) * 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US20060067933A1 (en) * 1999-01-07 2006-03-30 Gross Jane A Soluble receptor BR43x2 and methods of using
TR200101998T2 (tr) † 1999-01-07 2002-06-21 Zymogenetics, Inc. Çözünür reseptör BR 43x2 ve kullanım metodları
PL198934B1 (pl) 1999-01-25 2008-08-29 Apoxis Sa Zastosowanie przeciwciała swoistego wobec rozpuszczalnego BAFF lub aktywnego fragmentu przeciwciała i zastosowanie rozpuszczalnego BAFF lub jego aktywnego fragmentu
US6475986B1 (en) * 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
EP1157126A4 (en) 1999-02-24 2005-03-02 Gen Hospital Corp PROCESS FOR CLONING INTERMEDIATE PRODUCTS FOR SIGNAL TRANSDUCTION
AU3633000A (en) 1999-03-26 2000-10-16 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon
US6475987B1 (en) 1999-05-06 2002-11-05 National Jewish Medical And Research Center Tall-1 receptor homologues
DK1210425T4 (en) * 1999-08-17 2015-08-10 Apotech R & D Sa BAFF receptor (BCMA), an immunoregulatory agent
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
CA2399387C (en) 2000-02-11 2015-11-03 Biogen, Inc. Heterologous polypeptide of the tnf family
DK1255558T3 (da) † 2000-02-16 2006-10-23 Genentech Inc Anti-april antistoffer og hybridomaceller
US20040013674A1 (en) 2001-04-27 2004-01-22 Christine Ambrose Taci as an anti-tumor agent
US20020086018A1 (en) 2000-05-12 2002-07-04 Theill Lars Eyde Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3, and TACI
PT2275449T (pt) 2000-06-16 2016-12-27 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
CA2419661A1 (en) 2000-08-15 2002-03-07 Guo-Liang Yu Neutrokine-alpha and neutrokine-alpha splice variant
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
EP1456347A4 (en) 2001-11-16 2006-08-02 Human Genome Sciences Inc ANTIBODIES BINDING TO BLYS ACCORDING TO AN IMMUNOSPECIFIC MODE
AU2003221256A1 (en) 2002-02-21 2003-09-09 Biogen Idec Ma Inc. Use of bcma as an immunoregulatory agent
US7083735B2 (en) 2003-09-03 2006-08-01 Laing David A High debris content strainer
PT3415531T (pt) 2011-05-27 2023-09-12 Glaxo Group Ltd Proteínas de ligação a bcma (cd269/tnfrsf17
FR3005792B1 (fr) 2013-05-16 2017-12-29 Parknplug Procede de gestion dynamique et previsionnel du rechargement electrique de batteries

Also Published As

Publication number Publication date
RS51157B (sr) 2010-10-31
CZ300364B6 (cs) 2009-04-29
HU230583B1 (hu) 2017-02-28
US20180273605A1 (en) 2018-09-27
EP1806143A3 (en) 2007-07-18
JP5904985B2 (ja) 2016-04-20
US7691804B2 (en) 2010-04-06
US8828669B2 (en) 2014-09-09
EE200200071A (et) 2003-04-15
MXPA02001665A (es) 2003-07-14
JP4787439B2 (ja) 2011-10-05
PL354661A1 (en) 2004-02-09
JP5379107B2 (ja) 2013-12-25
IL148089A (en) 2015-03-31
HK1043608B (zh) 2007-12-07
SK288287B6 (sk) 2015-07-01
US20020165156A1 (en) 2002-11-07
EP1806143B1 (en) 2016-06-15
IL148089A0 (en) 2002-09-12
JP2014037434A (ja) 2014-02-27
DK1210425T4 (en) 2015-08-10
IL230961A0 (en) 2014-03-31
BR0013391A (pt) 2002-07-09
JP2003507364A (ja) 2003-02-25
EP1806143A2 (en) 2007-07-11
TR200201063T2 (tr) 2002-10-21
US20120214687A1 (en) 2012-08-23
DE60034579T3 (de) 2015-11-12
EP1210425B1 (en) 2007-04-25
US9650430B2 (en) 2017-05-16
DE60034579D1 (de) 2007-06-06
NO344346B1 (no) 2019-11-11
WO2001012812A2 (en) 2001-02-22
DE60034579T2 (de) 2008-01-31
NO20020789D0 (no) 2002-02-18
US20200095305A1 (en) 2020-03-26
JP2011063600A (ja) 2011-03-31
UA75049C2 (uk) 2006-03-15
HU227008B1 (en) 2010-04-28
EE05673B1 (et) 2013-08-15
JP2011116790A (ja) 2011-06-16
EA004635B1 (ru) 2004-06-24
CN100447244C (zh) 2008-12-31
US20020172674A1 (en) 2002-11-21
NO20020789L (no) 2002-04-08
HK1043608A1 (en) 2002-09-20
WO2001012812A3 (en) 2001-09-07
IS2955B (is) 2016-12-15
EA200200261A1 (ru) 2002-08-29
SK288603B6 (sk) 2018-10-01
NZ517782A (en) 2004-01-30
BG106519A (bg) 2003-04-30
AU6911200A (en) 2001-03-13
CN1379815A (zh) 2002-11-13
CA2383154A1 (en) 2001-02-22
HU1000128D0 (en) 2010-05-28
YU10602A (sh) 2005-06-10
EP2314694A2 (en) 2011-04-27
BRPI0013391B8 (pt) 2021-05-25
AU780240B2 (en) 2005-03-10
SK2292002A3 (en) 2002-07-02
US7083785B2 (en) 2006-08-01
KR100897082B1 (ko) 2009-05-14
ATE360693T1 (de) 2007-05-15
NO331410B1 (no) 2011-12-19
SK500172015A3 (hu) 2002-07-02
BRPI0013391B1 (pt) 2018-09-11
IS6273A (is) 2002-02-15
EP2314694A3 (en) 2013-12-11
KR20090016772A (ko) 2009-02-17
HU227947B1 (en) 2012-06-28
DK1210425T3 (da) 2007-09-17
US20150139992A1 (en) 2015-05-21
US20100040627A1 (en) 2010-02-18
NO20111232A1 (no) 2011-09-12
GEP20053685B (en) 2005-12-12
EP1210425A2 (en) 2002-06-05
EP1210425B2 (en) 2015-06-17
IL230961A (en) 2016-06-30
US10494416B2 (en) 2019-12-03
PL207501B1 (pl) 2010-12-31
CZ2002579A3 (cs) 2002-05-15
PL211786B1 (pl) 2012-06-29
KR20020084842A (ko) 2002-11-11
CA2383154C (en) 2013-04-30

Similar Documents

Publication Publication Date Title
HUP0203084A2 (en) Use of baff receptor (bcma) as an immunoregulatory agent
RU94038043A (ru) Применение замещенных производных аденина для лечения множественного склероза
MX9605940A (es) Compuestos bioaromaticos que llevan un grupo adamantilo en orto, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
TW376320B (en) Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
RU95108231A (ru) Glp-1-молекулярный комплекс, фармацевтическая композиция и способ получения комплекса
BG101118A (en) Therapeutical compounds
MX9501848A (es) Nuevos compuestos polienicos, composiciones farmaceuticas y cosmeticas que los contienen y sus usos.
NO20001087D0 (no) Medikament for forlengelse av muskelfunksjon eller behandling av muskelforstyrrelser eller -sykdommer
RU94045825A (ru) Применение материала, полученного из mycobacterium vaccae для производства терапевтического средства для лечения психических заболеваний, способ лечения психических заболеваний, продукт, содержащий антигенный и/или иммунорегуляторный материал, фармацевтическое средство
PL323364A1 (en) Bicyclic aromatic compounds
NZ328874A (en) Heterocyclic biaryl compounds and their use in pharmaceutical compositions for treatment of dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders
MX9805705A (es) Compuestos biaromaticos, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
MX9501849A (es) Nuevos compuestos biciclicos-aromaticos, composiciones farmaceuticas y cosmeticas que los contienen y sus usos.
HUP0102479A2 (hu) Neisseria meningitidis-ből származó BASBO29-polinukleotid(ok) és polipeptidek
ZA943553B (en) Tri(platinum) complexes
PL323363A1 (en) Biaromatic propynyl or dienyl compounds
DE69632396D1 (de) Behandlung von erkrankungen, die vom cytokinwachstumsfaktor verursacht werden
FR2756561B1 (fr) Composes heteroaryles, compositions pharmaceutiques et cosmetiques les contenant et utilisations
NZ324380A (en) Therapeutic benzimidazole compounds and their use in treatment of virus infections
ES2148572T3 (es) Derivados hidrosolubles de epipodofilotoxina, su procedimiento de preparacion, su utilizacion a titulo de medicamento, y su utilizacion destinada a los tratamientos anticancerosos.
NO995838L (no) Nye heteroetynylenforbindelser og farmasoeytiske og kosmetiske preparater inneholdende de samme
IL102032A0 (en) 2-amino-5-cyano-1,4-dihydropyridines,their preparation and pharmaceutical compositions containing them
PT1231908E (pt) Composicao farmaceutica compreendendo um composto dador de no e sua utilizacao em terapia
ATE293445T1 (de) Herstellung reiner stereoisomere von tricyclo- (5.2.1.0(2.6) )-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel
TW374085B (en) Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: TOPOTARGET SWITZERLAND SA, CH

Free format text: FORMER OWNER(S): APOTECH R & D S.A., CH; BIOGEN, INC., US

Owner name: BIOGEN IDEC MA INC., US

Free format text: FORMER OWNER(S): APOTECH R & D S.A., CH; BIOGEN, INC., US

HC9A Change of name, address

Owner name: BIOGEN MA INC., US

Free format text: FORMER OWNER(S): APOTECH R & D S.A., CH; BIOGEN, INC., US; BIOGEN IDEC MA INC., US

Owner name: TOPOTARGET SWITZERLAND SA, CH

Free format text: FORMER OWNER(S): APOTECH R & D S.A., CH; BIOGEN, INC., US; BIOGEN IDEC MA INC., US